139 related articles for article (PubMed ID: 18218786)
1. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.
Dirks NL; Nolting A; Kovar A; Meibohm B
J Clin Pharmacol; 2008 Mar; 48(3):267-78. PubMed ID: 18218786
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
[TBL] [Abstract][Full Text] [Related]
4. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
Azzopardi N; Lecomte T; Ternant D; Boisdron-Celle M; Piller F; Morel A; Gouilleux-Gruart V; Vignault-Desvignes C; Watier H; Gamelin E; Paintaud G
Clin Cancer Res; 2011 Oct; 17(19):6329-37. PubMed ID: 21953502
[TBL] [Abstract][Full Text] [Related]
6. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab.
Cézé N; Ternant D; Piller F; Degenne D; Azzopardi N; Dorval E; Watier H; Lecomte T; Paintaud G
Ther Drug Monit; 2009 Oct; 31(5):597-601. PubMed ID: 19730278
[TBL] [Abstract][Full Text] [Related]
7. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
8. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
9. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
10. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer.
Pointreau Y; Azzopardi N; Ternant D; Calais G; Paintaud G
Ther Drug Monit; 2016 Oct; 38(5):567-72. PubMed ID: 27631463
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
[TBL] [Abstract][Full Text] [Related]
13. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
[TBL] [Abstract][Full Text] [Related]
14. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
Bernier J
Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
[TBL] [Abstract][Full Text] [Related]
16. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.
Comet B; Kramar A; Faivre-Pierret M; Dewas S; Coche-Dequeant B; Degardin M; Lefebvre JL; Lacornerie T; Lartigau EF
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):203-9. PubMed ID: 22331006
[TBL] [Abstract][Full Text] [Related]
17. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer.
Ouellet D; Periclou AP; Johnson RD; Woodworth JR; Lalonde RL
Cancer Chemother Pharmacol; 2000; 46(3):227-34. PubMed ID: 11021740
[TBL] [Abstract][Full Text] [Related]
19. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
Panikkar RP; Astsaturov I; Langer CJ
Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
